Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 8, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 33.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 8, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 2, 2028 | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2031 | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) | Trial Milestone | Phase 3 |
| June 15, 2031 | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome | Trial Milestone | Phase 3 |
Track TSHA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TSHA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| June 25, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| June 22, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 19, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 4, 2025 | Quarterly results filed (8-K) | Earnings | — |
| October 16, 2025 | 8-K filed: Other event | Filing | — |
| October 9, 2025 | 8-K filed: Other event | Filing | — |
| October 2, 2025 | 8-K filed: Other event | Filing | — |
| August 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 29, 2025 | 8-K/A filed: Reg FD disclosure, Other event | Filing | — |
| May 29, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| May 28, 2025 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 15, 2025 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.